Filtered By:
Specialty: Cardiology
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 545 results found since Jan 2013.
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Polish Heart Journal - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research
Treatment of progressive ischemic stroke with low ‑dose eptifibatide: A retrospective case‑control study
Exp Ther Med. 2022 Nov 22;25(1):22. doi: 10.3892/etm.2022.11721. eCollection 2023 Jan.ABSTRACTProgressive ischemic stroke (PIS) is a therapeutic challenge in clinical practice. The present retrospective study aimed to investigate the safety and effectiveness of eptifibatide in the treatment of PIS. The present study enrolled patients with PIS admitted to Xiangtan Central Hospital (Xiangtan, China) between March 2020 and March 2021 with National Institutes of Health Stroke Scale (NIHSS) progression scores of ≥2 points during the initial 72 h. Patients were then divided into two groups according to their different anti-pla...
Source: Atherosclerosis - December 23, 2022 Category: Cardiology Authors: Long Luo Jinsheng Lin Ye Deng Zhigang Li Ying Yuan Wen Zhang Source Type: research
Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
ConclusionsIn patients who receive clopidogrel after PCI, concomitant use of PPI seems to increase the risk of major cardiovascular events.
Source: Cardiovascular Drugs and Therapy - November 11, 2022 Category: Cardiology Source Type: research
A 28-year-old male with spontaneous coronary artery dissection complicated by apical thrombus and acute ischemic stroke: An interesting case
Radiol Case Rep. 2022 Nov 2;18(1):246-249. doi: 10.1016/j.radcr.2022.10.001. eCollection 2023 Jan.ABSTRACTSpontaneous coronary artery dissection is described as the intramural bleeding that separates the layers of an epicardial coronary artery wall, either with or without an intimal tear. Atherosclerosis, iatrogenic damage, or trauma are not linked to this syndrome. Here we present a 28-year-old male with 1 month history stroke but no any chronic disease as well family history of heart disease who presented with 2 days' duration of typical cardiac chest pain. Based on an emergency electrocardiogram that showed biphasic T-w...
Source: Atherosclerosis - November 10, 2022 Category: Cardiology Authors: Said Abdirahman Ahmed Mesut Karata ş L ütfi Öcal Mohamed Abdullahi Mohamud Ishak Ahmed Abdi Mohamed Omar Hassan Source Type: research
Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study
Conclusions: During an extended follow-up of over 5 years after randomization, clopidogrel monotherapy as compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after PCI with DES.PMID:36342475 | DOI:10.1161/CIRCULATIONAHA.122.062770
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Jeehoon Kang Kyung Woo Park Huijin Lee Doyeon Hwang Han-Mo Yang Seung-Woon Rha Jang-Whan Bae Nam Ho Lee Seung Ho Hur Jung-Kyu Han Eun-Seok Shin Bon-Kwon Koo Hyo-Soo Kim Source Type: research
Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research
